Back

Risk of thromboembolic and haemorrhagic events associated with anticoagulation among 11,355 patients with non-valvular atrial fibrillation and thrombocytopenia

2 September 2024 (09:03 - 09:15)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations Oral Anticoagulation ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Mark Tam

The Chinese University of Hong Kong, Shatin (Hong Kong)

4 More presentations in this session

Presentation thumbnail
Predictors and outcomes of intracranial hemorrhage in 58,000 patients with atrial fibrillation on oral anticoagulation: insights from COMBINE-AF
Doctor M. Tannu (Durham, US)
Abstract Slides Video
Presentation thumbnail
Anticoagulation and stroke in hospitalized patients newly diagnosed with secondary atrial fibrillation: a population-based cohort study
Doctor H. Abdel-Qadir (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Post-operative atrial fibrillation during cardiac rehabilitation: incidence and long-term prognostic value.
Doctor S. Rastelli (IT)
Abstract Slides Video
Presentation thumbnail
Use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation across five stages of chronic kidney diseases
Doctor T. Chao (Taipei, TW)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations
Video

The Event

Event poster

ESC Congress 2024

2 September 2024 09:03 CET
You may be interested in
thumbnail
Congress Session
Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations
thumbnail
Congress Session
Global perspectives on anticoagulation: navigating clotting and bleeding
thumbnail
Congress Session
Personalised anticoagulation therapy in eligible patients with atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources